Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 4
Submit an article Journal homepage
6,109
Views
16
CrossRef citations to date
0
Altmetric
Original Article: Research

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib

Jacqueline C. BarrientosCLL Research and Treatment Program, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, USA; Correspondence[email protected]
View further author information
,
Jan A. BurgerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
John C. ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Peter HillmenDepartment of Haematology, The Leeds Teaching Hospitals, St. James University Hospital, Leeds, UK; View further author information
,
Cathy ZhouPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA; View further author information
,
Joi NinomotoPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA; View further author information
,
Danelle F. JamesPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA; View further author information
&
Thomas J. KippsDepartment of Medicine, University of California San Diego, Moores Cancer Center, San Diego, CA, USAView further author information
 show all
Pages 1000-1005 | Received 30 Apr 2018, Accepted 09 Aug 2018, Published online: 02 Oct 2018

References

  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
  • Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175–1184.
  • Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–1817.
  • Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28:2188–2196.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
  • IMBRUVICA® (Ibrutinib) prescribing information. Sunnyvale (CA): Pharmacyclics LLC; 2018.
  • Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
  • Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–1099.
  • Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211.
  • Burger JA, Sivina M, Ferrajoli A. Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib + R) in patients with chronic lymphocytic leukemia (CLL). Blood 2017;130:427.
  • Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–1189.
  • Chen SS, Chang BY, Chang S, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30:833–843.
  • Burger JA, Li KW, Keating MJ, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017;2:e89904.
  • Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase in peripheral blood lymphocytes [e-letter]. Blood. 2012. http://www.bloodjournal.org/content/111/12/5446/tab-e-lett ers?sso-checked=true#clarification-of-iwcll-criteria-for-a-partial-response-to-therapy.
  • Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437.
  • Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
  • Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
  • Brown JR, Hillmen P, O’Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32:83–91.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.